<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>170160_050</messagenumb>
		<messagesenderidentifier>NOVOPROD</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151548</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>JP-NOVOPROD-368904</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20130109</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130117</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>E2b Differences Report</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>JP-NOVOPROD-368904</companynumb>
		<primarysource>
			<reportercountry>JP</reportercountry>
			<qualification>3</qualification>
			<literaturereference>Tomomi Fujisawa, et.al. Effect of ciclosporin in an elderly patient with type 2 diabetes mellitus and positive anti-insulin antibodies test. The 49th Kinki Regional Meeting of the Japan Diabetes Society. 2012;p111</literaturereference>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVOPROD</senderorganization>
			<senderdepartment>Product Safety and Clinical Quality Assurance</senderdepartment>
			<sendergivename>Novo</sendergivename>
			<sendermiddlename>Nordisk</sendermiddlename>
			<senderfamilyname>Inc.</senderfamilyname>
			<senderstreetaddress>100 College Road West</senderstreetaddress>
			<sendercity>Princeton</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>08540</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>6099875831</sendertel>
			<sendertelcountrycode>1</sendertelcountrycode>
			<senderfax>6099878480</senderfax>
			<senderfaxcountrycode>1</senderfaxcountrycode>
			<senderemailaddress>NNPI_AE_REPORTING@NOVONORDISK.COM</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDAEDI.CDER</receiverdepartment>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3018276504</receivertel>
			<receivertelcountrycode>1</receivertelcountrycode>
			<receiveremailaddress>WTaylor@OC.FDA.GOV</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientonsetage>81</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientagegroup>6</patientagegroup>
			<patientsex>2</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Type 2 diabetes mellitus</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>duration not reported</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Anti-insulin antibody positive</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Anti-insulin antibody positive</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Anti-insulin antibody positive</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Haemoglobin A1C increased to 13.5%</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Haemoglobin A1C increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Glycosylated haemoglobin increased</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testname>HbA1C</testname>
				<testresult>13.5</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>HbA1C</testname>
				<testresult>12.5</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>HbA1C</testname>
				<testresult>7.2</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>NovoLin R CHU FlexPen</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb>UNKNOWN</drugbatchnumb>
				<drugauthorizationnumb>19-938</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Novo Nordisk A/S</drugauthorizationholder>
				<drugdosageform>Solution for injection</drugdosageform>
				<drugadministrationroute>058</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>INSULIN HUMAN</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>ZINC CHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anti-insulin antibody positive</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Reportable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anti-insulin antibody positive</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Probable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glycosylated haemoglobin increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Reportable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glycosylated haemoglobin increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Probable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>NovoLin R CHU FlexPen</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb>UNKNOWN</drugbatchnumb>
				<drugauthorizationnumb>19-938</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Novo Nordisk A/S</drugauthorizationholder>
				<drugdosageform>Solution for injection</drugdosageform>
				<drugadministrationroute>058</drugadministrationroute>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>INSULIN HUMAN</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>ZINC CHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anti-insulin antibody positive</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Reportable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anti-insulin antibody positive</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Probable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glycosylated haemoglobin increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Reportable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glycosylated haemoglobin increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Probable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>INSULIN GLULISINE</medicinalproduct>
				<drugadministrationroute>058</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>INSULIN GLULISINE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This serious Literature case titled "Effect of cyclosporin in an elderly patient with type 2 diabetes mellitus and positive anti-insulin antibodies test" referenced in " the 49th Kinki Regional Meeting of the Japan Diabetes Society (Author: Tomomi Fujisawa, et.al)" and was reported by a health care professional from Japan. It concerns a 81-year-old female patient with type II diabetes mellitus treated with NovoLin R Chu FlexPen (fast acting Insulin human) (as per the most sold list in Japan) on unknown dates and experienced "haemoglobin A1C increased to 13.5%" and "anti-insulin antibody positive" beginning on an unknown date.

Non-Novo Nordisk suspect drug included Insulin Glulisine on unknown dates due to type II diabetes mellitus.

Patient's height: not reported.

Medical history includes type 2 diabetes mellitus (duration not reported).

The patient received insulin treatment for 7 years. The patient had adequate glycemic control with human insulin at 0.5 unit/weight (kg)/day until HbA1c level increased to 13.5% despite increased dose of human insulin to 1.2 U/weight kg/day, and she was referred to the reporting hospital.  After hospitalization, insulin preparation was switched to aspart 2.0 units/weight (kg) /day and was discharged from hospital with temporal improvement followed by deterioration. 

The patient repeated the same course but the treatment was switched to Glulisine 2.8 units/ weight (kg)/day in the second hospitalization. Poor glycemic control persisted with HbA1c levels at 12.5% despite high dose of insulin at 5.4 U/weight (kg)/day. Contribution of anti-insulin antibodies was suspected and immunosuppressive therapy with cyclosporin was started. Subsequently, insulin dose was reduced rapidly.  One year later, blood glucose was controlled with HbA1c of 7.2% with insulin dose at 0.9 unit/weight (kg)/day.

Action taken to NovoLin R Chu FlexPen was reported as product discontinued and the action taken to Insulin Glulisine was reported as Unknown.

The overall outcome was recovered on an unknown date.

Since last submission, the case was updated with the following:
-Reporter causality changed to "probable"
-Outcome of events
-Narrative updated accordingly.

Comment: company comment: Human insulin is known to be antigenic, with low titres of antibodies developing in most patients (up to 80%). The effect of insulin antibodies on insulin pharmacokinetics, with the presence of binding IgG in serum, may delay time to peak levels of free insulin. Antibodies may be cross-reactive to both insulin aspart and human insulin.

 Becker KL: Principles and Practice of Endocrinology and Metabolism, third edition 2001. and Lindholm A et. al. Immune responses to insulin aspart. Diabetes Care 2002; 25: 876-82.</narrativeincludeclinical>
				<sendercomment>Human insulin is known to be antigenic, with low titres of antibodies developing in most patients (up to 80%). The effect of insulin antibodies on insulin pharmacokinetics, with the presence of binding IgG in serum, may delay time to peak levels of free insulin. Antibodies may be cross-reactive to both insulin aspart and human insulin.¹

¹ Becker KL: Principles and Practice of Endocrinology and Metabolism, third edition 2001. and Lindholm A et. al. Immune responses to insulin aspart. Diabetes Care 2002; 25: 876-82.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
